Natural Alternatives International (NAII) Competitors $3.75 +0.12 (+3.31%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAII vs. QNCX, WHWK, CABA, MIST, EPIX, JMAC, IMMX, ADAG, INKT, and VNRXShould you be buying Natural Alternatives International stock or one of its competitors? The main competitors of Natural Alternatives International include Quince Therapeutics (QNCX), Whitehawk Therapeutics (WHWK), Cabaletta Bio (CABA), Milestone Pharmaceuticals (MIST), ESSA Pharma (EPIX), Maxpro Capital Acquisition (JMAC), Immix Biopharma (IMMX), Adagene (ADAG), MiNK Therapeutics (INKT), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry. Natural Alternatives International vs. Its Competitors Quince Therapeutics Whitehawk Therapeutics Cabaletta Bio Milestone Pharmaceuticals ESSA Pharma Maxpro Capital Acquisition Immix Biopharma Adagene MiNK Therapeutics VolitionRx Natural Alternatives International (NASDAQ:NAII) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations. Which has better valuation & earnings, NAII or QNCX? Natural Alternatives International has higher revenue and earnings than Quince Therapeutics. Natural Alternatives International is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNatural Alternatives International$113.80M0.20-$7.22M-$1.39-2.70Quince TherapeuticsN/AN/A-$56.83M-$1.39-1.21 Do analysts rate NAII or QNCX? Quince Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 377.61%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Quince Therapeutics is more favorable than Natural Alternatives International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Natural Alternatives International 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Quince Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Is NAII or QNCX more profitable? Quince Therapeutics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -6.56%. Natural Alternatives International's return on equity of -10.34% beat Quince Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Natural Alternatives International-6.56% -10.34% -5.19% Quince Therapeutics N/A -117.52%-34.22% Do institutionals & insiders hold more shares of NAII or QNCX? 32.4% of Natural Alternatives International shares are owned by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are owned by institutional investors. 20.9% of Natural Alternatives International shares are owned by insiders. Comparatively, 20.3% of Quince Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media refer more to NAII or QNCX? In the previous week, Natural Alternatives International and Natural Alternatives International both had 1 articles in the media. Natural Alternatives International's average media sentiment score of 1.91 beat Quince Therapeutics' score of 0.93 indicating that Natural Alternatives International is being referred to more favorably in the media. Company Overall Sentiment Natural Alternatives International Very Positive Quince Therapeutics Positive Which has more risk & volatility, NAII or QNCX? Natural Alternatives International has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. SummaryNatural Alternatives International and Quince Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Natural Alternatives International News Delivered to You Automatically Sign up to receive the latest news and ratings for NAII and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NAII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAII vs. The Competition Export to ExcelMetricNatural Alternatives InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.18M$2.75B$5.59B$9.58BDividend YieldN/A1.78%4.71%4.03%P/E Ratio-2.709.4630.1020.52Price / Sales0.20681.15447.3598.21Price / CashN/A159.7936.0158.40Price / Book0.284.948.405.79Net Income-$7.22M$31.62M$3.25B$259.12M7 Day Performance2.74%-3.70%-1.83%-2.35%1 Month Performance14.33%8.88%8.28%9.02%1 Year Performance-34.55%-6.19%36.25%15.23% Natural Alternatives International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAIINatural Alternatives International1.4327 of 5 stars$3.75+3.3%N/A-35.6%$23.18M$113.80M-2.70290Positive NewsQNCXQuince Therapeutics2.8791 of 5 stars$1.90+0.5%$8.00+321.1%+122.7%$85.94MN/A-1.3760WHWKWhitehawk TherapeuticsN/A$1.85+2.8%N/AN/A$84.80M$25.98M11.5640CABACabaletta Bio3.0977 of 5 stars$1.64-1.8%$14.43+779.8%-77.6%$84.74MN/A-0.6550Positive NewsUpcoming EarningsMISTMilestone Pharmaceuticals2.9565 of 5 stars$1.49-5.7%$7.00+369.8%-1.4%$84.47M$1M-1.9130Positive NewsUpcoming EarningsEPIXESSA Pharma0.8238 of 5 stars$1.87-0.5%$2.00+7.0%-62.8%$83.45MN/A-2.9750Upcoming EarningsJMACMaxpro Capital AcquisitionN/A$6.21-3.7%N/A+2,924.6%$83.39MN/A0.002,021Gap UpIMMXImmix Biopharma3.6557 of 5 stars$2.99+0.7%$7.00+134.1%+22.2%$82.80MN/A-4.279News CoverageADAGAdagene2.7343 of 5 stars$1.93+10.3%$8.00+314.5%-10.7%$82.44M$100K0.00260INKTMiNK Therapeutics2.8287 of 5 stars$19.80-2.5%$37.50+89.4%+79.0%$80.95MN/A-7.8630Positive NewsHigh Trading VolumeVNRXVolitionRx1.5582 of 5 stars$0.78+14.8%$3.50+351.6%+6.4%$80.59M$1.31M-2.1580 Related Companies and Tools Related Companies Quince Therapeutics Competitors Whitehawk Therapeutics Competitors Cabaletta Bio Competitors Milestone Pharmaceuticals Competitors ESSA Pharma Competitors Maxpro Capital Acquisition Competitors Immix Biopharma Competitors Adagene Competitors MiNK Therapeutics Competitors VolitionRx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAII) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Natural Alternatives International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Natural Alternatives International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
